Amarin Corp rises as partner receives approval for heart drug in China

Amarin

01/06/2023 14:14

** Shares of biopharma co Amarin Corporation Plc  AMRN.O 
rise 5.26% to $1.23 premarket
    ** Co says EddingPharm, its commercial partner in China, has
received regulatory approval for its heart drug from China's
health authority
    ** The drug has been granted approval as an add-on to diet
to reduce levels of a type of blood fat known as triglyceride in
adult patients with severe hypertriglyceridemia
     ** Says partner is preparing for commercial launch in
China, expected by year-end
    ** Up to last close, stock down ~3% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))